The Assistant Secretary for Preparedness and Response (ASPR) and the US Food and Drug Administration (FDA) announced on August 27, 2021, changes in the authorized use of monoclonal antibodies bamlanivimab and etesevimab administered together under Emergency Use Authorization (EUA) 094.
The ASPR will resume distribution of bamlanivimab and etesevimab together and etesevimab alone to pair with the existing supply of bamlanivimab at a facility for use under EUA.
Monoclonal Antibody Combo Effective Against Delta Variant
Good Recovery at One Year for Most COVID-19 Hospital Survivors
However, survivors had more problems with mobility, pain or discomfort, anxiety or depression at one year than controls
COVID-19 Vaccine Hesitancy Up for Racial, Ethnic Minority HCWs
Vaccine hesitancy highest among Black and Hispanic or Latino health care workers; concerns include side effects, newness of vaccine
Prescriptions Rise for Veterinary Drug for COVID-19 Patients
Increase in demand for ivermectin has been accompanied by a fivefold increase in calls to poison control centers
High Demand for At-Home COVID-19 Tests Could Hamper Supply, Abbott Says
Sales have skyrocketed due to the surge in cases driven by the highly transmissible delta variant
Daily Average of COVID-19 Hospitalizations in U.S. Hits 100,000
COVID-19 deaths have also risen to an average of more than 1,000 a day for the first time since March
U.S. to Be Removed From European Union Safe Travel List
Change not mandatory; EU member nations can decide for themselves whether or not to impose the new measures